Cetuximab Biosimilar - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511246110

Publication Date:

November 21, 2024

Pages:

104

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Cetuximab Biosimilar was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Cetuximab Biosimilar was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cetuximab Biosimilar was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Cetuximab Biosimilar was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Cetuximab Biosimilar include Actavis, Amgen, Celltrion, Pfizer, Bio X Cell, Wuhan Dima Biotechnology and Guangdong ANNPO Biotechnology, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cetuximab Biosimilar, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Cetuximab Biosimilar by region & country, by Type, and by Application.
The Cetuximab Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cetuximab Biosimilar.
Market Segmentation
By Company
Actavis
Amgen
Celltrion
Pfizer
Bio X Cell
Wuhan Dima Biotechnology
Guangdong ANNPO Biotechnology
Segment by Type:
100 mg/50 mL Injection
200 mg/100 mL Injection
Segment by Application
Metastatic colorectal cancer
Metastatic breast cancer
Non-small cell lung cancer
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cetuximab Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Cetuximab Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Cetuximab Biosimilar in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Cetuximab Biosimilar Product Introduction
1.2 Global Cetuximab Biosimilar Market Size Forecast
1.2.1 Global Cetuximab Biosimilar Sales Value (2019-2030)
1.2.2 Global Cetuximab Biosimilar Sales Volume (2019-2030)
1.2.3 Global Cetuximab Biosimilar Sales Price (2019-2030)
1.3 Cetuximab Biosimilar Market Trends & Drivers
1.3.1 Cetuximab Biosimilar Industry Trends
1.3.2 Cetuximab Biosimilar Market Drivers & Opportunity
1.3.3 Cetuximab Biosimilar Market Challenges
1.3.4 Cetuximab Biosimilar Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Cetuximab Biosimilar Players Revenue Ranking (2023)
2.2 Global Cetuximab Biosimilar Revenue by Company (2019-2024)
2.3 Global Cetuximab Biosimilar Players Sales Volume Ranking (2023)
2.4 Global Cetuximab Biosimilar Sales Volume by Company Players (2019-2024)
2.5 Global Cetuximab Biosimilar Average Price by Company (2019-2024)
2.6 Key Manufacturers Cetuximab Biosimilar Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Cetuximab Biosimilar Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Cetuximab Biosimilar
2.9 Cetuximab Biosimilar Market Competitive Analysis
2.9.1 Cetuximab Biosimilar Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Cetuximab Biosimilar Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cetuximab Biosimilar as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 100 mg/50 mL Injection
3.1.2 200 mg/100 mL Injection
3.2 Global Cetuximab Biosimilar Sales Value by Type
3.2.1 Global Cetuximab Biosimilar Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Cetuximab Biosimilar Sales Value, by Type (2019-2030)
3.2.3 Global Cetuximab Biosimilar Sales Value, by Type (%) (2019-2030)
3.3 Global Cetuximab Biosimilar Sales Volume by Type
3.3.1 Global Cetuximab Biosimilar Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Cetuximab Biosimilar Sales Volume, by Type (2019-2030)
3.3.3 Global Cetuximab Biosimilar Sales Volume, by Type (%) (2019-2030)
3.4 Global Cetuximab Biosimilar Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Metastatic colorectal cancer
4.1.2 Metastatic breast cancer
4.1.3 Non-small cell lung cancer
4.1.4 Other
4.2 Global Cetuximab Biosimilar Sales Value by Application
4.2.1 Global Cetuximab Biosimilar Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Cetuximab Biosimilar Sales Value, by Application (2019-2030)
4.2.3 Global Cetuximab Biosimilar Sales Value, by Application (%) (2019-2030)
4.3 Global Cetuximab Biosimilar Sales Volume by Application
4.3.1 Global Cetuximab Biosimilar Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Cetuximab Biosimilar Sales Volume, by Application (2019-2030)
4.3.3 Global Cetuximab Biosimilar Sales Volume, by Application (%) (2019-2030)
4.4 Global Cetuximab Biosimilar Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Cetuximab Biosimilar Sales Value by Region
5.1.1 Global Cetuximab Biosimilar Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Cetuximab Biosimilar Sales Value by Region (2019-2024)
5.1.3 Global Cetuximab Biosimilar Sales Value by Region (2025-2030)
5.1.4 Global Cetuximab Biosimilar Sales Value by Region (%), (2019-2030)
5.2 Global Cetuximab Biosimilar Sales Volume by Region
5.2.1 Global Cetuximab Biosimilar Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Cetuximab Biosimilar Sales Volume by Region (2019-2024)
5.2.3 Global Cetuximab Biosimilar Sales Volume by Region (2025-2030)
5.2.4 Global Cetuximab Biosimilar Sales Volume by Region (%), (2019-2030)
5.3 Global Cetuximab Biosimilar Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Cetuximab Biosimilar Sales Value, 2019-2030
5.4.2 North America Cetuximab Biosimilar Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Cetuximab Biosimilar Sales Value, 2019-2030
5.5.2 Europe Cetuximab Biosimilar Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Cetuximab Biosimilar Sales Value, 2019-2030
5.6.2 Asia Pacific Cetuximab Biosimilar Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Cetuximab Biosimilar Sales Value, 2019-2030
5.7.2 South America Cetuximab Biosimilar Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Cetuximab Biosimilar Sales Value, 2019-2030
5.8.2 Middle East & Africa Cetuximab Biosimilar Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Cetuximab Biosimilar Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Cetuximab Biosimilar Sales Value
6.2.1 Key Countries/Regions Cetuximab Biosimilar Sales Value, 2019-2030
6.2.2 Key Countries/Regions Cetuximab Biosimilar Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Cetuximab Biosimilar Sales Value, 2019-2030
6.3.2 United States Cetuximab Biosimilar Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Cetuximab Biosimilar Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Cetuximab Biosimilar Sales Value, 2019-2030
6.4.2 Europe Cetuximab Biosimilar Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Cetuximab Biosimilar Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Cetuximab Biosimilar Sales Value, 2019-2030
6.5.2 China Cetuximab Biosimilar Sales Value by Type (%), 2023 VS 2030
6.5.3 China Cetuximab Biosimilar Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Cetuximab Biosimilar Sales Value, 2019-2030
6.6.2 Japan Cetuximab Biosimilar Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Cetuximab Biosimilar Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Cetuximab Biosimilar Sales Value, 2019-2030
6.7.2 South Korea Cetuximab Biosimilar Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Cetuximab Biosimilar Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Cetuximab Biosimilar Sales Value, 2019-2030
6.8.2 Southeast Asia Cetuximab Biosimilar Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Cetuximab Biosimilar Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Cetuximab Biosimilar Sales Value, 2019-2030
6.9.2 India Cetuximab Biosimilar Sales Value by Type (%), 2023 VS 2030
6.9.3 India Cetuximab Biosimilar Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Actavis
7.1.1 Actavis Company Information
7.1.2 Actavis Introduction and Business Overview
7.1.3 Actavis Cetuximab Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Actavis Cetuximab Biosimilar Product Offerings
7.1.5 Actavis Recent Development
7.2 Amgen
7.2.1 Amgen Company Information
7.2.2 Amgen Introduction and Business Overview
7.2.3 Amgen Cetuximab Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Amgen Cetuximab Biosimilar Product Offerings
7.2.5 Amgen Recent Development
7.3 Celltrion
7.3.1 Celltrion Company Information
7.3.2 Celltrion Introduction and Business Overview
7.3.3 Celltrion Cetuximab Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Celltrion Cetuximab Biosimilar Product Offerings
7.3.5 Celltrion Recent Development
7.4 Pfizer
7.4.1 Pfizer Company Information
7.4.2 Pfizer Introduction and Business Overview
7.4.3 Pfizer Cetuximab Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Pfizer Cetuximab Biosimilar Product Offerings
7.4.5 Pfizer Recent Development
7.5 Bio X Cell
7.5.1 Bio X Cell Company Information
7.5.2 Bio X Cell Introduction and Business Overview
7.5.3 Bio X Cell Cetuximab Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Bio X Cell Cetuximab Biosimilar Product Offerings
7.5.5 Bio X Cell Recent Development
7.6 Wuhan Dima Biotechnology
7.6.1 Wuhan Dima Biotechnology Company Information
7.6.2 Wuhan Dima Biotechnology Introduction and Business Overview
7.6.3 Wuhan Dima Biotechnology Cetuximab Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Wuhan Dima Biotechnology Cetuximab Biosimilar Product Offerings
7.6.5 Wuhan Dima Biotechnology Recent Development
7.7 Guangdong ANNPO Biotechnology
7.7.1 Guangdong ANNPO Biotechnology Company Information
7.7.2 Guangdong ANNPO Biotechnology Introduction and Business Overview
7.7.3 Guangdong ANNPO Biotechnology Cetuximab Biosimilar Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Guangdong ANNPO Biotechnology Cetuximab Biosimilar Product Offerings
7.7.5 Guangdong ANNPO Biotechnology Recent Development
8 Industry Chain Analysis
8.1 Cetuximab Biosimilar Industrial Chain
8.2 Cetuximab Biosimilar Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Cetuximab Biosimilar Sales Model
8.5.2 Sales Channel
8.5.3 Cetuximab Biosimilar Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Actavis
Amgen
Celltrion
Pfizer
Bio X Cell
Wuhan Dima Biotechnology
Guangdong ANNPO Biotechnology

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂